Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by rootsinsights and here's what we found interesting.
Average Info
Notes Per Post
0
Likes Per Post
0
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
14 hours
Number of Posts By Type
Link
5
Text
12
Last Seen Tumblr Blogs
Fun Fact
In 2020, 44% of users from Denmark used Tumblr daily.
Link
Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims Roots Analysis
Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria
Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings.
Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options.
To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html.
Key Market Insights
15+ therapies have been / are being developed for the treatment of different types of porphyria
More than 70% of the aforementioned candidates are currently under clinical evaluation. Further, three therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved for the treatment of different types of porphyria.
Around 50% of the therapeutics are being developed as biologics
Majority (over 65%) of the abovementioned biologic drugs have been / are being designed for administration via the intravenous route. Furthermore, majority of the drugs (37%) have been / are being targeting acute intermittent porphyria.
Over 30% of the therapies have been / are being developed for erythropoietic protoporphyria
More than 65% the abovementioned therapies are currently being evaluated in clinical phases. Further, around 60% of the aforementioned therapy candidates are being developed as small molecules.
More than 45% of the players evaluating therapies for porphyria are small companies
North America has emerged as a key hub for the development of porphyria therapies, featuring the presence of 65% developers. The developer landscape is further dominated by players that have been established between 2001-2010, representing around 45% of the total number of stakeholders.
A number of clinical trials evaluating therapies for porphyria, have been registered
Majority of the clinical studies have been completed. More than 30% of the overall trials are phase I studies. Further, it is worth noting that, most of the trials (~ 60%) focused on porphyria therapies were registered post-2010.
Partnership activity in this field has increased at a CAGR of 9.6%, between 2018 and 2020
More than 70% of the reported deals were established post-2018, with the maximum activity being reported in 2019 and 2020. Majority of the instances captured in the report were product distribution / commercialization agreements (~45%).
380+ articles have been published related to porphyria, since January 2018
Close to 20% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of erythropoietic protoporphyria. Example of prominent journals include (in decreasing order of number of publications) Molecular Genetics, Orphanet Journal of Rare Diseases, British Journal of Dermatology and Molecular Genetics, and Metabolism Reports.
Around 15 eminent individuals were identified as key opinion leaders (KOLs) in this domain
More than 65% of these KOLs were observed to be associated with organizations based in US, followed by those affiliated to institutes in Spain (20%) and South Africa (7%). Further, over 65% of the KOLs are currently affiliated to academic institutes, such as schools and universities.
North America is anticipated to capture over 60% of the global market share in 2030
In 2030, more than 50% of the market revenues are expected to be generated from sales of therapeutics intended for the treatment of erythropoietic protoporphyria and porphyria cutanea tarda. Further, therapies designed for oral route of administration are expected to occupy a larger share (51%) of the overall market, in the foreseen future.
To request a sample copy / brochure of this report, please visit this link.
Key Questions Answered
§ What are the prevalent R&D trends related to Porphyria?
§ What are the key challenges faced by stakeholders engaged in this domain?
§ What are the principal therapies developed by the companies in this domain?
§ Who are the leading industry and non-industry players in this market?
§ What are the key geographies where research on porphyria is actively being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts in this field?
§ What kind of partnership models are commonly adopted by industry stakeholders?
§ What are the factors that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the porphyria therapies market has been analyzed across the following segments:
§ Drug
§ GIVLAARI®
§ Panhematin®
§ SCENESSE®
§ MT-7117
§ Colestid
§ HARVONI®
§ Type of Porphyria
Acute Hepatic Porphyria
Acute Intermittent Porphyria
Erythropoietic Protoporphyria
Hereditary Coproporphyria
Porphyria Cutanea Tarda
Variegate Porphyria
X-Linked Porphyria
§ Route of Administration
Oral
Intravenous
Subcutaneous
§ Key Geographical Regions
North America
Europe
Asia-Pacific
The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.
§ Agios Pharmaceutical
§ Alnylam Pharmaceuticals
§ Clinuvel Pharmaceuticals
§ Disc Medicine
§ Mitsubishi Tanabe Pharma
§ Moderna Therapeutics
§ Palatin Technologies
§ Recordati Rare Diseases
For additional details, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html or email [email protected]
You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
The squamous non-small cell lung cancer market is projected to grow at a CAGR of 10.8% till 2030, claims Roots Analysis
Advances in molecular biology and tumor immunology have enabled the development of NSCLC targeting therapies, which have the ability to impede cancer growth by altering chemical reactions associated with oncogenic driver mutations
Roots Analysis has announced the addition of “Squamous Non-small Cell Lung Cancer Market, 2021-2031” report to its list of offerings.
Success of approved squamous non-small cell lung cancer therapies, such as Keytruda®, Opdivo® and Portrazza®, has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of these therapies to effectively treat NSCLC, an aggressive form of lung carcinoma, justifies its potential as a promising disease management recourse. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.
To order this 122+ page report, which features 81+ figures, please visit https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html
Key Market Insights
More than 85 product candidates are being investigated to treat metastatic or advanced squamous NSCLC patients
More than 78% of the therapies are being evaluated in early stages, either as monotherapies or in combination with other products. Further, majority of these therapies (45%) are designed for administration via the intravenous route. It is worth highlighting that, till date, five biologics and one small molecule have been approved for the treatment of squamous NSCLC.
Several big pharma players have an advanced pipeline of drugs targeting squamous NSCLC
Over 34 companies engaged in this domain represent large / very large businesses. Although biologics emerged as the most prominent type of molecule in the overall pipeline, big pharma players were observed to prefer developing small molecules against lung carcinomas. Interestingly, 53% of such firms are based in North America.
240+ clinical trials for squamous NSCLC therapy focused clinical trials were registered, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 56%, during the period 2017-2020. Of the total number of trials registered, close to 40% have already been completed, while 30% of the studies are actively recruiting participants.
Partnership activity has grown at an annualized rate of nearly 48%, between 2017 and 2020
Maximum number of partnerships were observed in 2020, indicating a recent increase in the activity. Majority of these agreements were reported to be product development and commercialization agreements, representing over 35% of the total number of instances.
The squamous non-small cell lung cancer market is projected to grow at a CAGR of 10.8% till 2030
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and growing demand for targeted and personalized therapeutic modalities. Biologics currently capture a significant market share, with the maximum revenue generation potential being associated with monoclonal antibodies; this trend is unlikely to change in the foreseen future.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html
Key Questions Answered
§ What are the prevalent R&D trends related to squamous non-small cell lung cancer?
§ What are the key challenges faced by stakeholders engaged in this domain?
§ What are the principal therapies being developed by the industry players?
§ Who are the leading industry and non-industry players in this market?
§ What are the contributions of big pharma players in this field?
§ What are the key geographies where research on squamous non-small cell lung cancer is being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts in this field?
§ What kind of partnership models are commonly adopted by industry stakeholders?
§ What are the factors that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the non-small cell lung cancer market has been analyzed across the following segments:
§ Type of Molecule
Biologics
Small molecules
§ Type of Therapy
Monotherapy
Combination therapy
§ Route of Administration
Intravenous
Intradermal
Oral
Subcutaneous
§ Key Geographical Regions
North America
Europe
Asia-Pacific and the Rest of World
The research includes detailed profiles of 22+ drugs being developed by key players (listed below); each profile features an overview of the developer, details related to its financial information (if available), recent developments and an informed future outlook.
§ Akesobio
§ Alphamab Oncology
§ Arcus Biosciences
§ Astrazeneca
§ BeiGene
§ Boehringer Ingelheim
§ Bristol Myers Squibb
§ Cadila Pharmaceuticals
§ Eli Lilly
§ GlaxoSmithKline
§ Hengrui Medicine
§ Henlius
§ Innovent Biologics
§ Junshi Biosciences
§ Macrogenics
§ Merck
§ Novartis
§ Pfizer
§ Regeneron
§ Roche
§ SinoCellTech
For additional details, please visit
https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html or email [email protected]
You may also be interested in the following titles:
1. RAS Targeting Therapies Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
The light activated therapies market is anticipated to grow at an annualized rate of 27.7% till 2030, claims Roots Analysis
Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products
London
Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030“ report to its list of offerings.
Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated therapies market is likely to witness significant growth in the foreseen future.
To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Market Insights
More than 125 marketed / under development light activated therapies form the current pipeline
At present, 13% of such therapies are marketed, while majority (82%) of the aforementioned candidates are still being evaluated in clinical phases. Examples of approved therapies include Ameluz®, Foscan®, Hemoporfin®, Metvix®, Photofrin® and Sarotalocan®.
Over 485 clinical trials are currently evaluating light activated therapies, worldwide
It is worth mentioning that most of the trials were / are being conducted in North America (34%). More than 28% patients enrolled in trials conducted in the aforementioned region were recruited across different sites in the United States. Further, 69% of the trials are being sponsored by non-industry players.
Over 635 patents have been filed / granted for light activated therapies, since 2018
Over 35% of these intellectual property documents were filed / granted in the North America, with maximum number of patents being filed in US. This is followed by Europe (33%), Asia Pacific and rest of the world (30%).
By 2030, the opportunity within the light activated therapies market is likely to be dominated by the North America
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and likely approval of several advanced stage therapy candidates. Further, Europe and North America (primarily the US) are expected to capture over 80% share of the total market (in terms of sales-based revenues), in 2030.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Questions Answered
§ What are the prevalent R&D trends related to light activated therapies?
§ What are the key therapeutic areas for which light activated therapies have been / are being developed?
§ What are the key challenges faced by stakeholders engaged in the manufacturing of light activated therapies?
§ Who are the leading industry and non-industry players engaged in the development of light activated therapies?
§ Across which geographies, extensive research related to light activated therapies is being conducted?
§ Which factors are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the light activated therapies market has been analyzed across the following segments:
§ Target Indication
§ Head and Neck Cancer
§ Actinic Keratosis
§ Macular Degeneration,
§ Polypoidal Choroidal Vasculopathy
§ Cervical Intraepithelial Neoplasia
§ Bladder Cancer
§ Barrett’s Esophagus
§ Gastric Cancer
§ Lung Cancer
§ Port-Wine Stain
§ Others
§ Key Players
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), details on product portfolio and recent developments, as well as an informed future outlook.
§ ADVANZ PHARMA
§ Biofrontera
§ biolitec Pharma
§ Luzitin
§ Nanospectra Biosciences
§ Photoatomic
§ Rakuten Medical
§ Steba biotech
§ Theralase
For additional details, please visit
https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
You may also be interested in the following titles:
1. Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Link
Innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers. The advantages of engaging such specialized service providers are numerous and enable sponsors to meet their clinical research timelines. In addition, SMOs can facilitate rapid patient recruitment, reduce study timelines, and manage the entire clinical trial processes and administrative work for their clients. Moreover, drug / medical device developers, and even the contract research organizations (CROs), can employ the therapeutic and operational expertise, global site networks and well-established processes and tools offered by SMOs in order to carry out their clinical research and site management activities in a cost and time-efficient manner.
Our Social Media Platform
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Link
The Regulatory T-Cell Therapies (Tregs) are a mature subpopulation of T-cells that play a critical role in mediating immunological tolerance to self-antigens and suppress immune responses that are harmful to the host, thereby, enabling homeostasis. These mainly develop in thymus from CD4+ thymocytes and are mainly of three types: natural Tregs, adaptive Tregs and invitro Tregs. Tregs can either be directly administered or can be transduced with T cell receptor (TCR) or chimeric antigen receptor (CAR) which have high affinity to target antigens. In recent years, Treg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo.
Our Social Media Platform
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Link
The global cancer burden is increasing rapidly with over 19 million new cancer cases and 10 million deaths reported in the year 2020. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases. With several programs having entered the clinical stages, myeloid cell targeting therapies have emerged as a novel strategy in the suite of cancer immunotherapy approaches.
All the blood and immune cells are formed from the hematopoietic stem cell, with multiple stepwise intermediates. The hematopoietic hierarchy is divided into two primary branches: the myeloid cells and lymphoid cells.
Our Social Media Platform
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Link
Innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers. The advantages of engaging such specialized service providers are numerous and enable sponsors to meet their clinical research timelines.
0 notes
Text
Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies, 2021-2030
To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Inclusions
§ A detailed assessment of the current market landscape of light activated therapies, with respect to current status of development (preclinical / discovery, phase I, phase I / II, phase II, phase II / III, phase III and approved), type of light activated therapy (photodynamic therapy, photoimmunotherapy and photothermal therapy), therapeutic area (oncological disorders (solid tumor), dental disorders, skin disorders, oncological disorders (hematological cancer) and others), type of photosensitive dye (methylene blue, phthalocyanine dye, indocyanine green, toluidine blue and phenothiazine hydrochloride), type of light (red light, blue light, infrared light, near-infrared light, visible light, ultraviolet light and daylight), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy), type of developer (industry / non-industry) and popular target indications (periodontitis, actinic keratosis, basal cell carcinoma, head and neck cancer, lung cancer, cholangiocarcinoma, dental caries, squamous cell carcinoma, acne, bladder cancer, COVID-19, pancreatic cancer, prostate cancer and others). In addition, the chapter includes analysis on the light activated therapy developer(s) based on various relevant parameters, including year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
§ Detailed profiles of marketed and late stage (phase III) clinical products; each profile features an overview of the company, therapy overview, clinical development status, clinical trial endpoints, dosage information, key insights, clinical trial endpoints and estimated sales revenue (2021-2030).
§ An in-depth analysis of completed, ongoing and planned clinical studies of various light activated therapies based on relevant parameters, such as trial registration year, study design and trial phase, type of masking and type of intervention model, year and trial recruitment status, type of sponsor, most active industry and non-industry players (in terms of number of registered trials conducted), purpose of study, emerging focus area, location of trial, and key geographical regions.
§ An analysis of patents filed / granted related to light activated therapies, till 2021. The instances have been analyzed based on various relevant parameters, such as publication year, type of patent, patent age, geographical location, CPC symbols, emerging focus areas, leading patent assignees, leading industry and non-industry players (in terms of number of patents filed / granted), patent benchmarking and valuation.
§ Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) including brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
§ Target Indication
§ Head and Neck Cancer
§ Actinic Keratosis
§ Macular Degeneration,
§ Polypoidal Choroidal Vasculopathy
§ Cervical Intraepithelial Neoplasia
§ Bladder Cancer
§ Barrett’s Esophagus
§ Gastric Cancer
§ Lung Cancer
§ Port-Wine Stain
§ Others
§ Key Players
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Questions Answered
§ What are the prevalent R&D trends related to light activated therapies?
§ What are the key therapeutic areas for which light activated therapies have been / are being developed?
§ What are the key challenges faced by stakeholders engaged in the manufacturing of light activated therapies?
§ Who are the leading industry and non-industry players engaged in the development of light activated therapies?
§ Across which geographies, extensive research related to light activated therapies is being conducted?
§ Which factors are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:
1. Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
The progressive supranuclear palsy (PSP) therapies market, is projected to grow at a CAGR of over 35% in the coming decade, predicts Roots Analysis
The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy
Roots Analysis is pleased to announce the publication of its recent study, titled, “Progressive Supranuclear Palsy Therapies Market, 2021-2030”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
§ A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products.
§ Detailed profiles of the players that are engaged in the development of drug products / therapies for progressive supranuclear palsy.
§ A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters.
§ A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs.
§ An in-depth analysis of grants awarded to various research institutes for the projects related to progressive supranuclear palsy, in the period between 2010 and July 2021.
§ An in-depth analysis of the published articles related to PSP and potential therapeutics based on the year of publication, top authors, key journals and emerging focus areas.
§ An analysis of the partnerships that have been inked by stakeholders in this domain since 2015, covering instances of research and development, licensing, product development, clinical trials, and other relevant types of deals.
§ An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II), taking into consideration target patient population, expected launch date, competitive landscape, annual treatment cost and likely adoption of the therapy.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Phase II Drugs
§ AZP2006
§ RT001
§ BRAVYL
§ Emeramide
§ NORTHERA
§ Type of Therapy
§ Curative
§ Symptomatic / Palliative
§ Regional Distribution
§ North America (US)
§ Europe (France, Germany, Italy, Spain, UK)
The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:
§ Daniel Brennan (Business and Operations Advisor, NeuroTau)
§ Fabrizio Stocchi (Director of the Parkinson’s Disease and Movement Disorders Research Center, IRCCS San Raffaele)
Key companies covered in the report
§ Alzprotect
§ Retrotope
§ Woolsey Pharmaceuticals
§ EmeraMed
§ Lundbeck
§ NeuroTau
For more information please click on the following link:
https://www.rootsanalysis.com/reports/progressive-supranuclear-palsy-market.html
Other Recent Offerings
1. Brain Concussion Market, 2021-2031
2. Hunter Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
3. Pediatric Brain Tumors: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
4. Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
5. Neuromyelitis Optica Spectrum Disorder (2nd Edition): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
Squamous Non-small Cell Lung Cancer Market, 2021-2031 by Roots Analysis
Over time, important advances in diagnosis and the development of versatile treatment options have translated into tangible improvements in the overall survival of lung cancer patients; several targeted therapies are being developed against squamous NSCLCs
Roots Analysis is pleased to announce the publication of its recent study, titled, “Squamous Non-small Cell Lung Cancer Market, 2021-2031.”
The report features an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities. In addition to other elements, the study includes:
§ A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products by development stage, type of therapy, route of administration, type of molecule, line of therapy, dose strength and dose frequency across the complete product development cycle, including all clinical and nonclinical stages.
§ Detailed drug profiles that are either approved or in late stages of development for the treatment of squamous non-small cell lung cancer have been presented, featuring overview of the company, overview of the drug, clinical trial information, recent developments (such as clinical trial results, collaborations and conferences) and estimated sales revenue.
§ A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
§ An analysis of the partnerships that have been established in the domain, over the last five years, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
§ A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status, and trial focus, highlighting leading sponsors, type of organization, and regional distribution of trials. In addition, it features an insightful clinical end-points analysis.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Type of Molecule
§ Biologics
§ Small molecules
§ Type of Therapy
§ Monotherapy
§ Combination therapy
§ Route of Administration
§ Intravenous
§ Intradermal
§ Oral
§ Subcutaneous
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific and the Rest of World
Key companies covered in the report
§ Akesobio
§ Alphamab Oncology
§ Arcus Biosciences
§ Astrazeneca
§ BeiGene
§ Boehringer Ingelheim
§ Bristol Myers Squibb
§ Cadila Pharmaceuticals
§ Eli Lilly
§ GlaxoSmithKline
§ Hengrui Medicine
§ Henlius
§ Innovent Biologics
§ Junshi Biosciences
§ Macrogenics
§ Merck
§ Novartis
§ Pfizer
§ Regeneron
§ Roche
§ SinoCellTech
For more information please click on the following link:
https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html
Other Recent Offerings:
1. RAS Targeting Therapies Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
IN PURSUIT OF A COMPETITIVE EDGE AND TO EVENTUALLY ESTABLISH THEMSELVES AS ONE-STOP SHOPS, STAKEHOLDERS ARE ACTIVELY CONSOLIDATING THEIR CAPABILITIES RELATED TO SMALL MOLECULE MANUFACTURING THROUGH MERGERS AND ACQUISITIONS
In recent years, there has been a significant increase in consolidation activity within the pharmaceutical contract manufacturing domain, representing a CAGR of 53%. This can be attributed to the rising competition within this domain. It is also worth highlighting that more than 60% of the agreements were signed post 2019. Further, 67% of the agreements were focused on the acquisition on entire companies. To Request for Sample report - https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html
In terms of the key value drivers, most of the deals in this domain were inked for geographical consolidation, followed by those signed for capability addition (36), geographical expansion (31) and capacity addition (27). Notable examples of agreements inked for gaining access to new technologies include (in alphabetical order of acquired company) acquisition of Aptuit by Evotec (2017), Dalton Pharma Services by Seikagaku (2020) and Orbis Biosciences by Adare Pharmaceuticals (2020).
To Request for customize report - https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market-2nd-edition-2018-2028/request-customization.html
It is worth highlighting that most of the acquired companies have a deal multiple value of more than 1.4; this can be attributed to the fact that acquired companies are likely to significantly boost the revenue generation potential of the acquirer in the foreseen future, given that the latter entity has invested significant capital in the transaction. Examples of companies that have been acquired for high values include (in decreasing order of value of deal amount) Patheon (USD 7.2 billion), Capsugel (USD 5.5 billion) and Cambrex (USD 2.4 billion).
The pharmaceutical contract manufacturing market is estimated to be worth USD 141 billion in 2030, growing at a CAGR of 6.1%, during the period 2021-2025, and 7.3%, over the period 2026-2030. It is worth highlighting that the outsourced component of the pharmaceutical API manufacturing market is likely to be worth USD 93 billion in 2030, growing at a CAGR of 6.4%. Further, the outsourced component of the pharmaceutical FDF manufacturing is likely to be worth USD 48 billion in 2030, growing at a CAGR of 7.3% during the forecast period.
In terms of the type of dosage form, the contract manufacturing market for oral solid dosage form is projected to reach USD 14 billion, in 2030, growing at a CAGR of 2.7%. Interestingly, the revenues generated from parenteral dosage form are projected to increase from USD 6.9 billion in 2021 to USD 19 billion in 2030, growing at a CAGR of 12%.
Since pharmaceutical contract manufacturing market is an established domain, with presence of numerous commercial products, the pharmaceutical contract manufacturing market for commercial scale of operation is likely to be worth USD 114 billion in 2030, growing at a CAGR of 5.9%, while the market for clinical scale of operation is likely to be worth USD 27 billion in 2030, growing at a CAGR of 11%. It is worth highlighting that clinical-stage products are anticipated to account for around 20% of the overall revenue share in 2030.
It must be noted that according to our base case projections, the pharmaceutical contract manufacturing market for parenteral / injectable form of packaging is likely to be worth USD 48 billion in 2030, growing at a CAGR of 13%, during the forecast period. Further, the contract manufacturing market for bottles and blister packaging is likely to be worth USD 30 billion and USD 25 billion, respectively, in 2030.
According to our base case projections, the pharmaceutical contract manufacturing market for large and very large players is likely to be worth USD 72 billion, in 2030. This can be attributed to the fact that these companies offer their products across various therapeutic areas. Further, the revenues generated from mid-sized and small pharmaceutical companies are likely to be worth USD 37 billion and USD 32 billion, respectively, in 2030. It is worth highlighting that the share of small pharmaceutical companies in the overall contract manufacturing market is anticipated to increase from 20% in 2021 to 23% in 2030.
It is worth mentioning that in terms of geographical distribution, the pharmaceutical contract manufacturing markets in North America and Europe are likely to grow at a CAGR of 6.6% and 5.9%, respectively. On the other hand, the emerging markets within the Asia-Pacific, Latin America, and Middle East and North Africa regions are estimated to grow at a CAGR of 7.3%, 5.1% and 7%, respectively.
To request for report, click under - https://www.rootsanalysis.com/reports/191/request-sample.html
Other Recent Offerings:
1. RAS Targeting Therapies Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
COMPANY COMPETITIVENESS ANALYSIS - ATTAINING A COMPETITIVE EDGE OVER OTHERS BY EXPLORING EXISTING POTENTIAL
Industry stakeholders are steadily expanding their existing capabilities in order to enhance their respective product portfolios and maintain a competitive edge in this steadily evolving market. The companies considered in this analysis have been divided into relevant peer groups (based on company size) and scored on the basis of various parameters, such as types of RTU containers, types of fabrication materials used for containers, types of RTU closures, types of fabrication materials used for closures, number of sterilization techniques used and compatible drug classes.
To Request for Sample report - https://www.rootsanalysis.com/reports/224/request-sample.html
Large players that have received high scores, as per our proprietary scoring criteria, include (arranged in decreasing order of competitiveness score) West Pharmaceutical Services, Stevanato Group, Daikyo Seiko and SCHOTT KAISHA. Amongst these players, West Pharmaceutical Services claims to be engaged in the manufacturing of 24 pre-sterilized / RTU closures (for vials and syringes) using different types of fabrication materials, such as rubber, plastic and metal. It is worth mentioning that most of the pre-sterilized / RTU primary packaging systems manufactured by the company are compatible with biologics, as well as small molecules. Further, Stevanato Group emerged as another prominent player, engaged in the manufacturing of 14 pre-sterilized / RTU primary packaging systems; further, it uses different techniques, such as (in alphabetical order) electron beam, ethylene oxide and steam, for sterilization of its products.
To Request for customize report - https://www.rootsanalysis.com/reports/view_document/pre-sterilized-ready-to-use-primary-packaging-market/224.html#overview
Moreover, Gerresheimer and Sartorius emerged as other prominent players, in terms of relative supplier strength, having an experience of 157 years and 151 years, respectively in the industry. It is worth highlighting that Gerresheimer is currently developing three pre-sterilized / RTU containers, which can be sterilized by both gamma-irradiation and steam.
During the period 2015-2020, more than 45 partnerships were established by stakeholders engaged in this domain. In the given time period, the maximum number of deals were recorded in 2020, followed by those inked in 2017.
Majority of the agreements focused on pre-sterilized / RTU primary packaging components were acquisitions (30%), followed by product / technology integration agreements (24%). Recent examples include (in reverse chronological order) acquisition of GCL Pharma by Bormioli Pharma (2020), Muller + Muller by DWK Life Sciences (2020), CSP Technologies by Aptar Pharma (2018), and Triveni Polymer by Gerresheimer (2018). Interestingly, industry players based in Europe were involved in majority of the intercontinental and intracontinental partnership agreements.
For additional details, To request for report, click under - https://www.rootsanalysis.com/reports/224/request-sample.html
You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
The light activated therapies market is anticipated to grow at an annualized rate of 27.7% till 2030, claims Roots Analysis
Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products
London
Roots Analysis has announced the addition of “Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030“ report to its list of offerings.
Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated therapies market is likely to witness significant growth in the foreseen future.
To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Market Insights
More than 125 marketed / under development light activated therapies form the current pipeline
At present, 13% of such therapies are marketed, while majority (82%) of the aforementioned candidates are still being evaluated in clinical phases. Examples of approved therapies include Ameluz®, Foscan®, Hemoporfin®, Metvix®, Photofrin® and Sarotalocan®.
Over 485 clinical trials are currently evaluating light activated therapies, worldwide
It is worth mentioning that most of the trials were / are being conducted in North America (34%). More than 28% patients enrolled in trials conducted in the aforementioned region were recruited across different sites in the United States. Further, 69% of the trials are being sponsored by non-industry players.
Over 635 patents have been filed / granted for light activated therapies, since 2018
Over 35% of these intellectual property documents were filed / granted in the North America, with maximum number of patents being filed in US. This is followed by Europe (33%), Asia Pacific and rest of the world (30%).
By 2030, the opportunity within the light activated therapies market is likely to be dominated by the North America
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and likely approval of several advanced stage therapy candidates. Further, Europe and North America (primarily the US) are expected to capture over 80% share of the total market (in terms of sales-based revenues), in 2030.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Questions Answered
§ What are the prevalent R&D trends related to light activated therapies?
§ What are the key therapeutic areas for which light activated therapies have been / are being developed?
§ What are the key challenges faced by stakeholders engaged in the manufacturing of light activated therapies?
§ Who are the leading industry and non-industry players engaged in the development of light activated therapies?
§ Across which geographies, extensive research related to light activated therapies is being conducted?
§ Which factors are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the light activated therapies market has been analyzed across the following segments:
§ Target Indication
§ Head and Neck Cancer
§ Actinic Keratosis
§ Macular Degeneration,
§ Polypoidal Choroidal Vasculopathy
§ Cervical Intraepithelial Neoplasia
§ Bladder Cancer
§ Barrett’s Esophagus
§ Gastric Cancer
§ Lung Cancer
§ Port-Wine Stain
§ Others
§ Key Players
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), details on product portfolio and recent developments, as well as an informed future outlook.
§ ADVANZ PHARMA
§ Biofrontera
§ biolitec Pharma
§ Luzitin
§ Nanospectra Biosciences
§ Photoatomic
§ Rakuten Medical
§ Steba biotech
§ Theralase
For additional details, please visit
https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
You may also be interested in the following titles:
1. Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies, 2021-2030
To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Inclusions
§ A detailed assessment of the current market landscape of light activated therapies, with respect to current status of development (preclinical / discovery, phase I, phase I / II, phase II, phase II / III, phase III and approved), type of light activated therapy (photodynamic therapy, photoimmunotherapy and photothermal therapy), therapeutic area (oncological disorders (solid tumor), dental disorders, skin disorders, oncological disorders (hematological cancer) and others), type of photosensitive dye (methylene blue, phthalocyanine dye, indocyanine green, toluidine blue and phenothiazine hydrochloride), type of light (red light, blue light, infrared light, near-infrared light, visible light, ultraviolet light and daylight), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy), type of developer (industry / non-industry) and popular target indications (periodontitis, actinic keratosis, basal cell carcinoma, head and neck cancer, lung cancer, cholangiocarcinoma, dental caries, squamous cell carcinoma, acne, bladder cancer, COVID-19, pancreatic cancer, prostate cancer and others). In addition, the chapter includes analysis on the light activated therapy developer(s) based on various relevant parameters, including year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).
§ Detailed profiles of marketed and late stage (phase III) clinical products; each profile features an overview of the company, therapy overview, clinical development status, clinical trial endpoints, dosage information, key insights, clinical trial endpoints and estimated sales revenue (2021-2030).
§ An in-depth analysis of completed, ongoing and planned clinical studies of various light activated therapies based on relevant parameters, such as trial registration year, study design and trial phase, type of masking and type of intervention model, year and trial recruitment status, type of sponsor, most active industry and non-industry players (in terms of number of registered trials conducted), purpose of study, emerging focus area, location of trial, and key geographical regions.
§ An analysis of patents filed / granted related to light activated therapies, till 2021. The instances have been analyzed based on various relevant parameters, such as publication year, type of patent, patent age, geographical location, CPC symbols, emerging focus areas, leading patent assignees, leading industry and non-industry players (in terms of number of patents filed / granted), patent benchmarking and valuation.
§ Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) including brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
§ Target Indication
§ Head and Neck Cancer
§ Actinic Keratosis
§ Macular Degeneration,
§ Polypoidal Choroidal Vasculopathy
§ Cervical Intraepithelial Neoplasia
§ Bladder Cancer
§ Barrett’s Esophagus
§ Gastric Cancer
§ Lung Cancer
§ Port-Wine Stain
§ Others
§ Key Players
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
Key Questions Answered
§ What are the prevalent R&D trends related to light activated therapies?
§ What are the key therapeutic areas for which light activated therapies have been / are being developed?
§ What are the key challenges faced by stakeholders engaged in the manufacturing of light activated therapies?
§ Who are the leading industry and non-industry players engaged in the development of light activated therapies?
§ Across which geographies, extensive research related to light activated therapies is being conducted?
§ Which factors are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:
1. Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
PHARMACEUTICAL CONTRACT MANUFACTURING - CURRENT MARKET LANDSCAPE
During our study, we were able to identify close to 500 players that are engaged in offering pharmaceutical contract manufacturing services. It is worth mentioning, most of the players (174) engaged in this domain offer contract manufacturing services for FDF / fill-finish operations, followed by those offering services for both API and FDF / fill-finish development (144).
To Request for Sample report - https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html
As can be observed in the figure, the pharmaceutical market is currently dominated by the presence of large and very large players (47%), followed by mid-sized firms (42%) and small companies (11%). Notable examples of well-established players engaged in this domain include (large and very large companies, in alphabetical order) Alembic Pharmaceutical, Angelini Pharma, Divi’s Laboratories, Fresenius Kabi and Lubrizol Life Sciences.
It is worth highlighting that, most of the pharmaceutical CMOs are based in Asia Pacific (50%), followed by those headquartered in Europe (26%) and North America (21%). Further, within Europe, most of the CMOs are based in Italy (19), followed by those headquartered in Germany (18), Spain (16), the UK (13), Switzerland (13) and France (12).
To Request for customize report - https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market-2nd-edition-2018-2028/request-customization.html
In terms of the type of service(s) offered, most of the companies engaged in this domain offer services for method development, and packaging and labelling (62%, each), followed by those offering scale-up services (58%) and formulation development services (52%). Notable examples of players offering all types of services include (in alphabetical order) AMRI, Altasciences, Almac, Catalent, MiPharm, Patheon and Recipharm
To request for report, click under - https://www.rootsanalysis.com/reports/191/request-sample.html
Other Recent Offerings
1. Brain Concussion Market, 2021-2031
2. Hunter Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
3. Pediatric Brain Tumors: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
4. Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
5. Neuromyelitis Optica Spectrum Disorder (2nd Edition): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes
Text
PRE-STERILIZED / READY-TO-USE PRIMARY PACKAGING MARKET - GAINING POPULARITY IN THE PHARMACEUTICAL INDUSTRY AND THE RISING FUTURE POTENTIAL
Primary packaging, such as vials, syringes, and cartridges, and their affiliated closures, play a vital role in ensuring the stability, and sterility, and thereby, the overall quality, efficacy and safety of a drug product. Moreover, the packaging bears the product label, which provides information related to the drug and, in certain cases, dosing instructions.[1] Pharmaceutical packaging is typically carried out under controlled conditions; specifically, for therapeutics that are designed for parenteral administration, fill / finish is carried out in sterile and aseptic environments. It is also crucial for innovators (or packaging service providers) to choose the appropriate, high quality primary packaging for their respective products; this is because the packaging material is in direct contact with the drug / therapy.[2] Building and maintaining the necessary expertise and infrastructure to support pharmacological fill / finish is a capital-intensive ordeal. Further, the growing complexity of modern pharmacological interventions, such as monoclonal antibodies, cell and gene therapies (which are typically produced in small batches) and the gradual (but imminent) shift to personalized therapies, has prompted drug developers to look for leaner manufacturing and packaging solutions. In this context, cost optimization is important and one of the available ways to save both time and capital is by bypassing manual processing and sterilization of primary packaging and switching to ready-to-use (RTU) formats.
To Request for Sample report - https://www.rootsanalysis.com/reports/224/request-sample.html
Pre-sterilized RTU container-closure systems have gradually become very popular and are widely used in the modern pharmaceutical industry. As indicated earlier, such components significantly simplify the overall fill / finish process, primarily by eliminating the need for several additional steps (such as washing, drying and sterilization), which were previously required to prepare primary containers for filling. In other words, using RTU components helps improve operational efficiencies.[3] In this context, it is worth highlighting that RTU packaging systems were in high demand during the COVID-19 pandemic, when novel vaccines and experimental therapies needed to be produced, and packaged for distribution in large quantities.[4] The surge in demand for appropriate packaging solutions in adequate quantities, is likely to persist, significantly adding to the opportunity for RTU package and affiliated closure developers / suppliers.
Presently, more than 150 pre-sterilized / RTU primary packaging systems, including cartridges, syringes and vials, as well as their respective closure systems are available worldwide. Majority (50%) of the pre-sterilized / RTU primary packaging systems are closures, followed by containers (34%) and container-closure systems (16%). It is worth highlighting that, of the total, 54 closures are suitable for use with vials, 19 are suitable for use with syringes and the remaining 5 are compatible with cartridges.
Amongst the primary packaging containers, vials and syringes emerged as the most common types of pre-sterilized / RTU containers manufactured by stakeholders engaged in this domain. This can be attributed to the fact that these containers are the most suitable for packaging of small volume of therapeutics, such as biologics, cell therapies, small molecules, vaccines and other potent products.
To Request for customize report - https://www.rootsanalysis.com/reports/view_document/pre-sterilized-ready-to-use-primary-packaging-market/224.html#overview
Further, glass emerged as the most preferred fabrication material used for pre-sterilized / RTU containers. Of these, majority (83%) of the containers are made of type I borosilicate glass, followed by those fabricated using type II treated soda-lime glass (10%) and type III soda-lime glass (7%). This is followed by pre-sterilized / RTU containers fabricated using plastic (29%), primarily cyclic olefin polymer. Examples include (in alphabetical order) ClearVial (MedicoPack), Daikyo Crystal Zenith Insert Needle Syringe Systems (Daikyo Seiko), Daikyo Crystal Zenith Ready to Use Vials (Daikyo Seiko) and SCHOTT TopPac sensitive (SCHOTT).
Sterilization of primary packaging systems is considered to be an essential step in the overall healthcare manufacturing process as it deactivates various forms of contaminating agents (particularly referring to bacteria, fungi, protozoa and viruses). Majority (43%) of the pre-sterilized / RTU containers are sterilized using ethylene oxide, followed by those employing steam sterilization (34%).
Presently, close to 50 companies claim to be actively involved in the manufacturing of pre-sterilized / RTU primary packaging systems. The market landscape is highly fragmented, featuring a mix of small (less than 50 employees, 17%), mid-sized (51-500 employees, 37%), large (501-1,000 employees, 2%) and very large (more than 1,000 employees, 44%) companies. The pre-sterilized / RTU packaging manufacturers market is fragmented, featuring the presence of established players as well as new entrants, which are well distributed across different geographical regions. Examples of established players include (in decreasing order of experience) Gerresheimer (1864), Sartorius (1870), SCHOTT (1884), DWK Life Sciences (1887), SGD Pharma (1896) and Becton, Dickinson and Company (1897).
To request for report, click under - https://www.rootsanalysis.com/reports/224/request-sample.html
Other Recent Offerings:
1. RAS Targeting Therapies Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
0 notes